Resources
- sort by:
- Relevance
- Date
- Popularity
- With New CV Drugs, Gilead Tests Its Commitment to Efficiency
- Gilead received some good news today with the results of a positive phase 3 study of its new high-blood pressure drug, darusentan. Combined with Gilead's purchase of CV Therapeutics to gain the chronic angina drug Ranexa, this marks a new push into the cardio-vascular area for a...
- Blog posts 2009-04-03
- Gilead Q1: Company Is Recession Resistant But Not Lawsuit Resistant
- Yet another gravity-defying quarter at Gilead: Revenues were up 22 percent to $1.5 billion; net income was up 21 percent to $589 million. But same bad news lurks behind the numbers in the form of a shareholder lawsuit that was given the go-ahead by the US Supreme Court a few...
- Blog posts 2009-04-22
- It’s Good News, Bad News for Gilead’s HIV Pill
- The good news: The FDA approved Viread, Gilead’s dwindling HIV treatment, as a therapy for hepatitis B. The drug’s sales had gone down to $613 million from a peak of $783 million as newer combination drugs -- including Gilead’s own Atripla, which includes Viread -- eroded the market for standalone...
- Blog posts 2008-08-12
- Gilead Executive Pay: Modest Raises for Outstanding Performance
- Gilead CEO John C Martin got a negligible pay raise in 2008, despite the fact that his company largely met its performance goals. Revenue was up, net income was up, and the stock price held (it's still double the price it was in 2004). Yet Martin's total...
- Blog posts 2009-03-16
- Gilead's FDA Warning Letter Contains Lesson About the Internet
- Gilead learned a lesson about the internet this week, namely that everything on it lives forever. Gilead received a warning letter from the FDA citing "false or misleading" statements about pulmonary hypertension drug Letairis made by one of its representatives at a medical conference. The letter was dated Feb. 27,...
- Blog posts 2009-03-06
- Gilead Sciences to Acquire Degussa's Raylo Chemicals Inc.; Purchase to Expand Gilead's Manufacturing Scale-Up Capacity for Investigational Therapies
- FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has signed a definitive agreement under which Gilead plans to acquire Canadian subsidiary Raylo Chemicals Inc. and most of its assets from Germany-based, specialty chemicals company Degussa AG. Under the terms of the agreement, which are subject...
- Research articles 2006-06-06
- Gilead Earnings Sound Death Knell (Again) for Large Sales Forces
- Gilead's third quarter numbers blew everyone away -- revenues up 30 percent, net income up 26.5 percent.The numbers call into question the value of large sales forces. A couple of days ago BNET noted that Abbott Labs got a "spectacular" $3.63 per dollar spent on marketing. The...
- Blog posts 2008-10-18
- Gilead Sciences gains FDA approval for Emtriva. (Life Sciences).
- GILEAD SCIENCES Inc. has received Food and Drug Administration FDA approval for Emtriva emtricitabine, an antiretroviral. Estimates for Emtriva as a co-formulated product with Gilead's first HIV drug Viread tenofovir top $1 billion, upon a pr GILEAD SCIENCES Inc. has received Food and Drug...
- Research articles 2003-07-14
- Gilead completes Triangle buy. (News in Brief).(Gilead Sciences Inc., Triangle Pharmaceuticals Inc.)(Brief Article)
- Gilead Sciences Inc. has completed its cash tender offer for all outstanding stock of Triangle ... Gilead Sciences Inc. has completed its cash tender offer for all outstanding stock of Triangle Pharmaceuticals Inc. at $6 per share. Gilead expects the merger to be completed...
- Research articles 2003-01-20
- Gilead Reduces Price of Viread in the Developing World by 37 Percent; Anti-HIV Medication Available to 68 Resource-Limited Countries Through the Gilead Access Program
- FOSTER CITY, Calif. -- Gilead Sciences (Nasdaq:GILD) today announced a significant price reduction for VireadR tenofovir disoproxil fumarate in the developing world. Gilead provides Viread, a once-a-day antiretroviral medication for HIV to be used in combination therapy, through the Gilead Access Program at a no-profit price in every country in...
- Research articles 2004-07-09
- OSI Gains Oncology Assets From Gilead. (News).(OSI Pharmaceuticals Inc., Gilead Sciences Inc.)(Brief Article)
- OSI PHARMACEUTICALS has agreed to acquire the assets of the oncology business of Gilead Sciences. The deal, worth up to $200 million, gives OSI a pipeline of clinical candidates in oncology and the related intellectual property, as well as Gilead's OSI PHARMACEUTICALS has agreed...
- Research articles 2001-12-03
- Gilead Invests $25 Million in Corus Pharma; Establishes Equity Position in Company With Late-Stage Product Candidate for Cystic Fibrosis
- FOSTER CITY, Calif. & SEATTLE -- Gilead Sciences, Inc. (Nasdaq:GILD) and Corus Pharma, Inc. today announced that Gilead has invested $25 million in Corus, a privately-held Seattle-based company focused on the development of novel drugs for respiratory diseases. In return for the investment, Gilead will receive preferred shares in Corus...
- Research articles 2006-04-12
- Gilead Sciences and the Institute of Organic Chemistry and Biochemistry Establish New Academic Research Centre in Prague; Donation by Gilead Honors Leadership of Dr. Antonin Holy in Antiviral Drug Discovery and Development
- FOSTER CITY, Calif. & PRAGUE, Czech Republic -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced a donation to The Institute of Organic Chemistry and Biochemistry at the Academy of Sciences of the Czech Republic IOCB for the establishment of a Gilead Sciences Research Centre. Gilead will provide a $1.1 million annual...
- Research articles 2006-07-13
- Gilead Sciences to Present at the Banc of America Securities 2004 Healthcare Conference on Friday, May 21st; Webcast Available Through Gilead Corporate Website
- Business Editors/Health/Medical Writers BIOWIRE2K FOSTER CITY, Calif.--BUSINESS WIRE--May 18, 2004 Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its corporate presentation will be webcast from the Banc of America Securities 2004 Healthcare Conference in Las Vegas, Nevada. This webcast may be accessed via the company's corporate website at...
- Research articles 2004-05-18
- CORRECTING and REPLACING Gilead Sciences to Present at the Banc of America Securities 2004 Healthcare Conference on Friday, May 21st
- Business Editors/Health/Medical Writers CORRECTION...by Gilead Sciences BIOWIRE2K FOSTER CITY, Calif.--BUSINESS WIRE--May 19, 2004 In BW6055 issued May 18, 2004: Second graph, first sentence of release dated May 18, 2004 should read: Friday, May 21st (sted Friday, March 21st). The corrected release reads: GILEAD SCIENCES...
- Research articles 2004-05-19
- Gilead Sciences to Present at the 23rd Annual JPMorgan Healthcare Conference on Monday, January 10th; Webcast Available Through Gilead Corporate Website
- FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its corporate presentation will be webcast from the 23rd Annual JPMorgan Healthcare Conference, in San Francisco, CA. This webcast may be accessed via the company's corporate website at www.gilead.com. John Martin, PhD, Gilead's President and Chief Executive Officer,...
- Research articles 2005-01-05
- Gilead Sciences to Present at the NASDAQ 18th Investor Program on Thursday, December 7
- Webcast Available Through Gilead Corporate Website FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) announced today that it will be webcasting a presentation on the company from the NASDAQ 18th Investor Program in London, United Kingdom. This audio only webcast may be accessed via the company's corporate website at...
- Research articles 2006-12-01
- Gilead Sciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Tuesday, February 5
- Webcast Available Through Gilead Corporate Website FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its corporate presentation will be webcast from the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference, taking place February 5 - 7, 2008 in New York. This webcast may be accessed...
- Research articles 2008-01-30
- Gilead Sciences to Present at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30
- Webcast Available Through Gilead Corporate Website FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its corporate presentation will be webcast from the Morgan Stanley Global Healthcare Unplugged Conference in Key Biscayne, Florida. This webcast may be accessed via the company's corporate website at www.gilead.com. John...
- Research articles 2008-04-24
- Gilead Sciences to Present at the 22nd Annual JPMorgan Healthcare Conference on Monday, January 12th; Webcast Available Through Gilead Corporate Website
- Business Editors/Health/Medical Writers JPMorgan Healthcare Conference FOSTER CITY, Calif.--BUSINESS WIRE--Jan. 9, 2004 Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its corporate presentation will be webcast from the 22nd Annual JPMorgan Healthcare Conference in San Francisco, California. This webcast may be accessed via the company's corporate website at...
- Research articles 2004-01-09
- << Previous
- page 1 of 30
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
